dimarts, 15 de setembre del 2015

MassDevice.com +3 | The top 3 medtech stories for September 15, 2015

plus3-1x1

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Losses widening, Unilife pares workforce by 17%

MassDevice.com news

Unilife said it plans to lay off about 50 workers, or roughly 17% of its workforce, after reporting wider losses for its fiscal 4th quarter and full-year 2015 and missing expectations on Wall Street.

Saying it now has a lineup of products to cover its target markets, York, Pa.-based Unilife said it’s looking to lower its operating expenses by cutting its R&D spend by 25% to 30% and reducing its sales, general & administrative costs by about 20%. Earlier this month Unilife tapped Morgan Stanley to help it evaluate “strategic alternatives.” Read more


2. Cardiovascular Systems reveals CEO Martin’s cancer diagnosis

MassDevice.com news

Cardiovascular Systems revealed that president & CEO David Martin will stay on the job while he undergoes treatment for Stage II stomach cancer.

In a letter to employees, Martin wrote yesterday that his doctors believe his condition is curable. Read more


1. Medtronic signs 10-year deal with Minnesota Vikings

MassDevice.com news

Medtronic said it signed a 10-year partnership with the Minnesota Vikings NFL team that includes sponsoring the “Medtronic Plaza,” a square connected to the team’s stadium.

The deal will put Medtronic’s moniker on the 3-acre gateway to the U.S. Bank Stadium the team plays in, as well as a community service program with the team and a permanent display of the company’s technological innovations inside the stadium. Read more

The post MassDevice.com +3 | The top 3 medtech stories for September 15, 2015 appeared first on MassDevice.



from MassDevice http://ift.tt/1KQECr5

Cap comentari:

Publica un comentari a l'entrada